Menu

CRILA FORTE - Solution for Treatment of the benign prostatic hyperplasia & fibroid uterus

In the clinical trial, the extract of Crinum latifolium L. var. Crilae Tram & Khanh has the effect of inhibiting enzyme 5- α reductase, so that testosterone does not turn into dihydrotestosterone , which is one  of the causes of prostatic hyperplasia.

Crila Forte is a product manufactured from the extract of the Crinum latifolium L. var. Crilae Tram & Khanh in Viet Nam.

The Alcaloids contained in the product include: 9-octadecenamide, dihydro-oxo-demethoxyhaemanthamine, augustamine, oxoassoanine, crinane-3α-ol, buphanidrine, powelline, undulatine, ambelline, 6-hydroxybuphanidine, 6-hydroxypowelline, crinamidine , 6-hydroxyundulatine, 1β, 2β-epoxyambelline, epoxy-3,7-dimethoxycrinane-11-one, 6-hydroxycrinamidine.

In the clinical trial, the extract of Crinum latifolium L. var. Crilae Tram & Khanh has the effect of inhibiting enzyme 5- α reductase, so that testosterone does not turn into dihydrotestosterone , which is one  of the causes of prostatic hyperplasia. The clinical trial of Crila Forte showed the results:

- A study of 179 men with benign prostatic hypertrophy aged between 50 and 87 at three centers. After 60 days of treatment, 89.18% achieved good results (decreased prostate size, decreased urinary frequency). The drug has a clear effect after 2 weeks of use.

- Study on 157 women with uterine fibroids aged between 26 and 55, tumors <6cm at three centers. After 90 days of treatment 79.5% gave very good results and satisfied requirements

  • The ratio of tumor's diameter reduced more than 50%: 3.6%
  • The ratio of tumor's diameter reduced 20% - 49%: 25.6%
  • The ratio of tumor's diameter reduced 10-19%: 19.5%
  • The ratio of tumor's diameter ungrow or reduced no more than 10%: 30.8%

The product is manufactured by factory certifcated GMP-WHO and GACP-WHO plantations. Crila Forte has been exported to the US market named Crila For Prostate

Other news